GPT and melanoma: In the phase III clinical trial Checkmate 067, patients with advanced melanoma treated with ipilimumab plus nivolumab presented a higher alanine aminotransferase (ALT) increase (19%) when compared to those receiving ipilimumab (4%) or nivolumab (4%), while the increase in aspartate aminotransferase (AST) was 17%, 4%, and 4%, respectively [17].